Role of Simvastatin as an Immunomodulator in Type 2 Diabetes
نویسندگان
چکیده
منابع مشابه
Role of simvastatin as an immunomodulator in type 2 diabetes: response to Lopes-Virella et al.
OBJECTIVE To test the hypothesis that simvastatin reduces the levels of circulating immune complexes (ICs) containing modified lipoproteins (mLDLs; mLDL-ICs), which may represent an additional mechanism for the reduced incidence of cardiovascular events in patients treated with simvastatin. RESEARCH DESIGN AND METHODS A total of 26 patients with type 2 diabetes and triglyceride levels <400 mg...
متن کاملGad65 as an Immunomodulator in Type 1 Diabetes
Type 1 diabetes (T1D) is caused by a deficiency of insulin as a result of an autoimmune destruction of the pancreatic β-cells. A possibility to preserve remaining β-cells in children with newly diagnosed T1D is of great importance since sustained β-cell function is recognized to result in reduced end-organ complications. Glutamic acid decarboxylase 65 (GAD65) is one of the major antigens target...
متن کاملInvestigating the Molecular miRNAs as Biomarkers of Type 2 Diabetes
Introduction: Biomarkers would significantly improve the early detection of the disease and identification of individuals at risk of emerging complications. Diabetes mellitus is a group of diverse and complex metabolic disorders. Both type 1 diabetes (T1D) and type 2 diabetes (T2D) mellitus are associated with distinct alterations in the profile of MicroRNAs (miRNAs) in the blood, which are som...
متن کاملEffects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes
OBJECTIVE To assess the effects of inhibited gastrointestinal cholesterol absorption in statin-treated dyslipidemic patients. RESEARCH DESIGN AND METHODS In a multicenter prospective randomized double-blind placebo-controlled trial, we primarily compared by ANCOVA the effect of 2-month ezetimibe (10 mg/day) or placebo therapy on LDL cholesterol serum levels in 108 type 2 diabetic patients wit...
متن کاملSuppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes.
OBJECTIVE Receptor for advanced glycation end products (AGEs) (RAGE) plays a central role in the process of plaque rupture in diabetic patients. Recently, it has been reported that RAGE may be downregulated by improving glycemic control. In contrast, despite being well known that RAGE may be induced in human vessels in a glucose-independent fashion, also by myeloperoxidase (MPO)-dependent AGE g...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Diabetes Care
سال: 2004
ISSN: 0149-5992,1935-5548
DOI: 10.2337/diacare.27.4.908